HELIOS-B Trial: Vutrisiran Benefits in ATTR-CM Treatment

The HELIOS-B trial, a Phase 3 study, evaluated vutrisiran for ATTR-CM, showing reduced mortality risk, improved quality of life, and manageable safety. It highlights efficacy in cardiovascular morbidity but notes limitations like non-randomized comparisons and limited diversity.